



a²

1. A compound of the formula (I):



wherein R¹ is a 5- to 6- membered aromatic ring which has a group of the formula:



wherein R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group,

X is a substituted or unsubstituted alkylene chain, and

Z¹ and Z² are respectively hetero-atoms, and which may have a further substituent,

the group R may bind to the 5- to 6- membered aromatic ring to form a ring,

Y is a substituted or unsubstituted imino group,

R² and R³ are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group;

or a salt thereof.

✓

a³

4. The compound according to claim 1, wherein the 5- to 6-membered aromatic ring is benzene.

contd.
a³

5. The compound according to claim 1, wherein R is a halogenated or unhalogenated lower alkyl group.

6. The compound according to claim 1, wherein X is $-(CH_2)_n-$

wherein n is an integer of 1-4.

7. The compound according to claim 1, wherein Z¹ and Z² are respectively $-O-$, $-S(O)_m-$

wherein m is an integer of 0-2 or $-N(R^4)-$

wherein R⁴ is a hydrogen atom or an optionally substituted lower alkyl group.

8. The compound according to claim 1, wherein Z¹ is $-O-$ or $-S(O)_m-$

wherein m is an integer of 0-2.

10. The compound according to claim 1, wherein Z² is $-O-$ or $-N(R^4)-$

wherein R⁴ is a hydrogen atom or a substituted or unsubstituted lower alkyl group.

12. The compound according to claim 1, wherein Y is $-N(R^5)-$

wherein R⁵ is a hydrogen atom, a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted acyl group.

13. The compound according to claim 12, wherein R⁵ is C₁₋₄ alkyl, formyl or C₂₋₅ alkanoyl.

14. The compound according to claim 12, wherein R⁵ is a group represented by the formula $-(CH_2)_k-R^6$; wherein k is 0 or 1, and R⁶ is a substituted or unsubstituted 5- to 6- membered monocyclic aromatic group.

15. The compound according to claim 1, wherein R² is a substituted or unsubstituted straight

contd.
a 5

chain hydrocarbon group.

16. The compound according to claim 1, wherein R^2 is an optionally substituted lower alkyl group.

17. The compound according to claim 1, wherein R^3 is a substituted or unsubstituted alicyclic hydrocarbon group or a substituted or unsubstituted alicyclic heterocyclic group.

✓

a 6

23. A compound selected from the group consisting of 7-(4-ethoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-ethyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-ethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-ethoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-formyl-7-(4-propoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-formyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethoxyphenyl)-1-propyl-2,3-dihydro-1-benzazepine-4-carboxamide, 1-benzyl-7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-cyclopropylmethyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-

100183221-1212001

contd.
a⁶

10018321 121201


(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-
1-phenyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3,4-
methylenedioxy)phenyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-
2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(2-methyloxazol-5-
yl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-
benzazepine-4-carboxamide, 1-allyl-7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-
(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 7-
(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-
1-(3-thienyl)methyl-2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-
N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-2-yl)methyl-
2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-methylpyrazol-
4-yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-
1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(3-methylisothiazol-4-
yl)methyl-N-[4-[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-2,3-dihydro-1-
benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-(1-ethylpyrazol-4-yl)methyl-N-
[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-
4-carboxamide, 7-(4-butoxyethoxyphenyl)-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-
5-yl)amino]methyl]phenyl]-2,3-dihydro-1-benzazepine-4-carboxamide, 1-isobutyl-N-[4-
[[N-methyl-N-(tetrahydropyran-5-yl)amino]methyl]phenyl]-7-(4-propoxyethoxyphenyl)-
2,3-dihydro-1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-
(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(thiazol-5-yl)methyl-2,3-dihydro-1-
benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-
(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(1-methyltetrazol-5-yl)methyl-2,3-dihydro-
1-benzazepine-4-carboxamide, 7-(4-butoxyethoxyphenyl)-N-[4-[[N-methyl-N-
(tetrahydropyran-4-yl)amino]methyl]phenyl]-1-(2-methyltetrazol-5-yl)methyl-2,3-dihydro-

contd.
Q 6


1-benzazepine-4-carboxamide and salts thereof.

Q 7

25. A method for producing a compound of the formula I:



wherein R¹ is a 5- to 6- membered aromatic ring which has a group of the formula:



wherein R is a hydrogen atom or a substituted or unsubstituted
hydrocarbon group,

X is a substituted or unsubstituted alkylene chain, and

Z¹ and Z² are respectively hetero-atoms, and which may have a further
substituent,

the group R may bind to the 5- to 6- membered aromatic ring to form a
ring,

Y is a substituted or unsubstituted imino group,


R² and R³ are respectively a substituted or unsubstituted aliphatic hydrocarbon group or a
substituted or unsubstituted alicyclic heterocyclic group;

or a salt thereof, which comprises subjecting a


10018321.121201

contd.
a⁷

compound of the formula:



wherein R¹ and Y are as defined above, a salt or reactive derivative thereof to a condensation reaction with a compound of the formula:



wherein R² and R³ are as defined above, or a salt thereof;

and then optionally isolating said compound of formula I or a salt thereof.

26. A pharmaceutical composition which comprises the compound according to claim 1 or a salt thereof and a pharmaceutically acceptable carrier, excipient, binder or diluent.

29. The composition according to claim 26, which is for the treatment of infectious diseases of HIV.

30. The composition according to claim 26, which for the treatment of AIDS.

35. A method for treating infectious diseases of HIV comprising administering a pharmaceutically effective amount of a compound of claim 1 or a salt thereof in combination with a protease inhibitor, a reverse transcriptase inhibitor or a combination thereof

contd.
a 9

to a mammal in need thereof.

a 10

37. A method for treating AIDS comprising administering a pharmaceutically effective amount of a compound of claim 1 or a salt thereof to a mammal in need thereof.

10018321.121201